James Sapirstein - 03 Jun 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Chief Executive Officer
Issuer ticker: COCP
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 16:10:45 UTC
Prior SEC filing: 15 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ James Sapirstein

Key filing fact

James Sapirstein filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 03 Jun 2026.

Key facts

This page summarizes James Sapirstein's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 16:10.

Change

Previous filing in this sequence was filed on 15 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559509 Primary reporting owner

SAPIRSTEIN JAMES

Relationship: Chief Executive Officer
Address: 4400 BISCAYNE BLVD.,, MIAMI
Signature: /s/ James Sapirstein
Signature date: 03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +235,000
Change %
Price: $0.000000^*
Shares after: 235,000
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 235,000
Exercise price: $1.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan.